Insmed Inc. (NASDAQ:INSM)’s share price rose 1.9% during mid-day trading on Thursday . The company traded as high as $13.20 and last traded at $13.20, with a volume of 73,895 shares. The stock had previously closed at $12.95.

INSM has been the topic of a number of research reports. Zacks Investment Research downgraded Insmed from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Wednesday, June 15th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $24.00 price target on shares of Insmed in a research note on Thursday, June 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $23.57.

The firm’s market cap is $824.20 million. The company’s 50-day moving average is $12.05 and its 200 day moving average is $11.85.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.03. Analysts predict that Insmed Inc. will post ($2.25) EPS for the current fiscal year.

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.